Cassandra J. Vandenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cassandra J. Vandenberg has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Clare L. Scott
Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
11 shared publications - Justin Bedo
Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
10 shared publications - Matthew John Wakefield
Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
10 shared publications - Anthony T. Papenfuss
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
9 shared publications - Holly E. Barker
Cancer Biology and Stem Cells Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
9 shared publications - Olga Kondrashova
QIMR Berghofer Medical Research Institute, Brisbane, Australia
9 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Springer Nature in Research Square
Multi-omics analysis of distinct hybrid epithelial/mesenchymal states in ovarian carcinosarcoma infers functional diversity and therapeutic vulnerabilities
Ovarian carcinosarcoma (OCS) is a rare and aggressive malignancy characterised by epithelial (carcinomatous) and mesenchymal (sarcomatous) components. This biphasic nature arises through epithelial-to-mesenchymal transition (EMT), which is a continuum involving transient and reversible states intermediate between full epithelial and mesenchymal extremes. Hybrid epithelial/mesenchymal (E/M) cell states display elevated epithelial-to-mesenchymal plasticity, and are likely drivers of tumour initiation, metastasis, immune evasion, and drug resistance in many cancer types. Therapeutic targeting of highly drug-resistant mesenchymal cells has resulted in discordant outcomes, potentially due to the enrichment of these remarkably plastic and aggressive partial EMT (p-EMT) states, which may represent promising targets for novel therapies. Using single-nucleus RNA sequencing and spatial transcriptomics, we characterised an extensive cohort of OCS patient-derived xenograft models to elucidate genes and signalling pathways associated with hybrid E/M cell states. We demonstrated that genes implicated in DNA replication and repair, cell cycle progression, and neurotransmitter signalling were over-represented in intermediate EMT cell states, underpinning their enhanced proliferative and dynamic nature. These p-EMT states were also enriched for genes involved in multiple signal transduction pathways previously implicated in EMP, including MAPK and Wnt signalling. As EMT regulation in cancer is complex and multi-layered, we used flow cytometry and cell surface proteomics to identify surface proteins associated with p-EMT states in OCS, including DPP4 as a prominent candidate for therapeutic targeting, alongside B7-H4/VTCN1, MUC15, and GGT1. We highlight novel therapeutic approaches for individuals with OCS and, potentially, other highly aggressive and drug-resistant cancers, where EMT is a key feature.
- 16 November 2026
- Published by Springer Nature in Research Square
Open AccessMulti-omics analysis of distinct hybrid epithelial/mesenchymal states in ovarian carcinosarcoma infers functional diversity and therapeutic vulnerabilities
Ovarian carcinosarcoma (OCS) is a rare and aggressive malignancy characterised by epithelial (carcinomatous) and mesenchymal (sarcomatous) components. This biphasic nature arises through epithelial-to-mesenchymal transition (EMT), which is a continuum involving transient and reversible states intermediate between full epithelial and mesenchymal extremes. Hybrid epithelial/mesenchymal (E/M) cell states display elevated epithelial-to-mesenchymal plasticity, and are likely drivers of tumour initiation, metastasis, immune evasion, and drug resistance in many cancer types. Therapeutic targeting of highly drug-resistant mesenchymal cells has resulted in discordant outcomes, potentially due to the enrichment of these remarkably plastic and aggressive partial EMT (p-EMT) states, which may represent promising targets for novel therapies. Using single-nucleus RNA sequencing and spatial transcriptomics, we characterised an extensive cohort of OCS patient-derived xenograft models to elucidate genes and signalling pathways associated with hybrid E/M cell states. We demonstrated that genes implicated in DNA replication and repair, cell cycle progression, and neurotransmitter signalling were over-represented in intermediate EMT cell states, underpinning their enhanced proliferative and dynamic nature. These p-EMT states were also enriched for genes involved in multiple signal transduction pathways previously implicated in EMP, including MAPK and Wnt signalling. As EMT regulation in cancer is complex and multi-layered, we used flow cytometry and cell surface proteomics to identify surface proteins associated with p-EMT states in OCS, including DPP4 as a prominent candidate for therapeutic targeting, alongside B7-H4/VTCN1, MUC15, and GGT1. We highlight novel therapeutic approaches for individuals with OCS and, potentially, other highly aggressive and drug-resistant cancers, where EMT is a key feature.
- Open Access
- 8 July 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (7) , 1152-1163
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial
Background: Homologous recombination (HR) deficiency (HRD) from germline BRCA1/2 mutations (gBRCAm) sensitizes high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) to PARP inhibitors (PARPi), as may promoter methylation of BRCA1 (me BRCA1 ) or RAD51C (me RAD51C ) or mutation of non-BRCA HR genes. This trial evaluated olaparib in platinum-sensitive, relapsed HGSOC (PSROC) and metastatic TNBC (mTNBC) with non-gBRCA HRD. Methods: Single-arm phase 2 trial of olaparib 300 mg orally twice daily. Tumour me BRCA1/ me RAD51C determined by methylation-sensitive, high-resolution melting PCR and targeted sequencing. Unmethylated cases underwent HR gene mutation testing. Primary outcome: objective tumour response rate (OTRR) at 6 months(m). Secondary outcomes: progression-free survival (PFS), OTRR according to HR gene aberration, and safety. Results: Total 22 enrolled: promoter methylation detected in 8/15 HGSOC and 5/7 TNBC, and pathogenic variants (PV) in non- BRCA HR genes. OTRR at 6 m was 40% HGSOC and 0% TNBC. OTRR was 38% in methylated cases vs 43% for other HRD. 6 m/12 m PFS were 53% / 25% (HGSOC), and 17% / 0% (TNBC). Conclusions: Olaparib demonstrated activity in HGSOC beyond gBRCAm, including with me BRCA1 or gRAD51C PV. Olaparib had limited activity in pre-treated TNBC. Effects of prior chemotherapy on me BRCA1/ me RAD51C require exploration to improve patient selection for PARPi. Clinical trials registration: Australian New Zealand Clinical Trials Registry Registration number ACTRN 12617000855325.
- 8 July 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (7) , 1152-1163
Open AccessOlaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial
Background: Homologous recombination (HR) deficiency (HRD) from germline BRCA1/2 mutations (gBRCAm) sensitizes high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) to PARP inhibitors (PARPi), as may promoter methylation of BRCA1 (me BRCA1 ) or RAD51C (me RAD51C ) or mutation of non-BRCA HR genes. This trial evaluated olaparib in platinum-sensitive, relapsed HGSOC (PSROC) and metastatic TNBC (mTNBC) with non-gBRCA HRD. Methods: Single-arm phase 2 trial of olaparib 300 mg orally twice daily. Tumour me BRCA1/ me RAD51C determined by methylation-sensitive, high-resolution melting PCR and targeted sequencing. Unmethylated cases underwent HR gene mutation testing. Primary outcome: objective tumour response rate (OTRR) at 6 months(m). Secondary outcomes: progression-free survival (PFS), OTRR according to HR gene aberration, and safety. Results: Total 22 enrolled: promoter methylation detected in 8/15 HGSOC and 5/7 TNBC, and pathogenic variants (PV) in non- BRCA HR genes. OTRR at 6 m was 40% HGSOC and 0% TNBC. OTRR was 38% in methylated cases vs 43% for other HRD. 6 m/12 m PFS were 53% / 25% (HGSOC), and 17% / 0% (TNBC). Conclusions: Olaparib demonstrated activity in HGSOC beyond gBRCAm, including with me BRCA1 or gRAD51C PV. Olaparib had limited activity in pre-treated TNBC. Effects of prior chemotherapy on me BRCA1/ me RAD51C require exploration to improve patient selection for PARPi. Clinical trials registration: Australian New Zealand Clinical Trials Registry Registration number ACTRN 12617000855325.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Supplementary methods and figures
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Supplementary methods and figures
- Open Access
- 5 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in platinum-sensitive recurrent ovarian cancer (n = 114). We also evaluate the utility of CUP-CC assay, an immune signature of C-C chemokine receptor type 4 up-regulation, chemokines, and cytokines. Priming with olaparib, or cyclophosphamide-olaparib, followed by durvalumab-olaparib, are both associated with longer PFS compared to olaparib monotherapy, but do not reach the pre-specified primary endpoint of 36-week trial threshold (PFS36). PFS36 rates are 47.4% (95% CI, 31.0-62.1; olaparib priming then olaparib-durvalumab), 48.7% (32.5-63.2; olaparib-cyclophosphamide then olaparib-durvalumab) and 35.1% (20.4-50.3; olaparib monotherapy). PFS is significantly longer for the homologous recombination deficient (N = 71) as compared to the proficient (HRP) (N = 29) subgroups (Hazard Ratio (HR) 0.55, 0.35-0.87). CUP-CC+ subgroup (N = 58) has a significantly longer PFS (HR 0.31, 0.19-0.49) than CUP-CC- (N = 46). Future studies should investigate whether CUP-CC has the potential to personalize poly (ADP-ribose) polymerase inhibitor therapies for patients who are BRCA wild-type, including HRP patients.
- 5 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessOlaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in platinum-sensitive recurrent ovarian cancer (n = 114). We also evaluate the utility of CUP-CC assay, an immune signature of C-C chemokine receptor type 4 up-regulation, chemokines, and cytokines. Priming with olaparib, or cyclophosphamide-olaparib, followed by durvalumab-olaparib, are both associated with longer PFS compared to olaparib monotherapy, but do not reach the pre-specified primary endpoint of 36-week trial threshold (PFS36). PFS36 rates are 47.4% (95% CI, 31.0-62.1; olaparib priming then olaparib-durvalumab), 48.7% (32.5-63.2; olaparib-cyclophosphamide then olaparib-durvalumab) and 35.1% (20.4-50.3; olaparib monotherapy). PFS is significantly longer for the homologous recombination deficient (N = 71) as compared to the proficient (HRP) (N = 29) subgroups (Hazard Ratio (HR) 0.55, 0.35-0.87). CUP-CC+ subgroup (N = 58) has a significantly longer PFS (HR 0.31, 0.19-0.49) than CUP-CC- (N = 46). Future studies should investigate whether CUP-CC has the potential to personalize poly (ADP-ribose) polymerase inhibitor therapies for patients who are BRCA wild-type, including HRP patients.
- Open Access
- 12 March 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (3) , e70274
Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models
- 12 March 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (3) , e70274
Open AccessFarletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models
- Open Access
- 4 May 2023
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-20
Targeting homologous recombination deficiency in uterine leiomyosarcoma
Background: Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of some individuals benefiting from poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy, which targets this DNA repair defect. In this report, we screened individuals with uLMS, accrued nationally, for mutations in the HR repair pathway and explored new approaches to therapeutic targeting. Methods: A cohort of 58 individuals with uLMS were screened for HR Deficiency (HRD) using whole genome sequencing (WGS), whole exome sequencing (WES) or NGS panel testing. Individuals identified to have HRD uLMS were offered PARPi therapy and clinical outcome details collected. Patient-derived xenografts (PDX) were generated for therapeutic targeting. Results: All 13 uLMS samples analysed by WGS had a dominant COSMIC mutational signature 3; 11 of these had high genome-wide loss of heterozygosity (LOH) (> 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous pathogenic alteration in an HR gene (deletion in BRCA2). A further three samples harboured homozygous HRD alterations (all deletions in BRCA2), detected by WES or panel sequencing, with 5/58 (9%) individuals having HRD uLMS. All five individuals gained access to PARPi therapy. Two of three individuals with mature clinical follow up achieved a complete response or durable partial response (PR) with the subsequent addition of platinum to PARPi upon minor progression during initial PR on PARPi. Corresponding PDX responses were most rapid, complete and sustained with the PARP1-specific PARPi, AZD5305, compared with either olaparib alone or olaparib plus cisplatin, even in a paired sample of a BRCA2-deleted PDX, derived following PARPi therapy in the patient, which had developed PARPi-resistance mutations in PRKDC, encoding DNA-PKcs. Conclusions: Our work demonstrates the value of identifying HRD for therapeutic targeting by PARPi and platinum in individuals with the aggressive rare malignancy, uLMS and suggests that individuals with HRD uLMS should be included in trials of PARP1-specific PARPi.
- 4 May 2023
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-20
Open AccessTargeting homologous recombination deficiency in uterine leiomyosarcoma
Background: Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of some individuals benefiting from poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy, which targets this DNA repair defect. In this report, we screened individuals with uLMS, accrued nationally, for mutations in the HR repair pathway and explored new approaches to therapeutic targeting. Methods: A cohort of 58 individuals with uLMS were screened for HR Deficiency (HRD) using whole genome sequencing (WGS), whole exome sequencing (WES) or NGS panel testing. Individuals identified to have HRD uLMS were offered PARPi therapy and clinical outcome details collected. Patient-derived xenografts (PDX) were generated for therapeutic targeting. Results: All 13 uLMS samples analysed by WGS had a dominant COSMIC mutational signature 3; 11 of these had high genome-wide loss of heterozygosity (LOH) (> 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous pathogenic alteration in an HR gene (deletion in BRCA2). A further three samples harboured homozygous HRD alterations (all deletions in BRCA2), detected by WES or panel sequencing, with 5/58 (9%) individuals having HRD uLMS. All five individuals gained access to PARPi therapy. Two of three individuals with mature clinical follow up achieved a complete response or durable partial response (PR) with the subsequent addition of platinum to PARPi upon minor progression during initial PR on PARPi. Corresponding PDX responses were most rapid, complete and sustained with the PARP1-specific PARPi, AZD5305, compared with either olaparib alone or olaparib plus cisplatin, even in a paired sample of a BRCA2-deleted PDX, derived following PARPi therapy in the patient, which had developed PARPi-resistance mutations in PRKDC, encoding DNA-PKcs. Conclusions: Our work demonstrates the value of identifying HRD for therapeutic targeting by PARPi and platinum in individuals with the aggressive rare malignancy, uLMS and suggests that individuals with HRD uLMS should be included in trials of PARP1-specific PARPi.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Supplementary methods and figures
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Supplementary methods and figures
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Supplementary methods and figures
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Supplementary methods and figures